Shamburg News · 8-K filed Nov 18, 2026, 8:16 AM EST
GeneDx Names Everett Cunningham CEO as Katherine Stueland Steps Down
WGS · GeneDx Holdings Corp.
- Leadership change
- Materiality: high
On November 15, 2026, GeneDx Holdings Corp. agreed that CEO Katherine Stueland will step down as CEO and resign from the Board effective on Everett Cunningham's start date, expected on or before December 15, 2026, and will remain as Executive Advisor through January 31, 2027. The Board appointed Everett Cunningham as CEO and Class II director effective on the same Transition Date, with a $750,000 initial base salary, a $1,050,000 sign-on cash bonus, and a $10.0 million RSU grant. Ms. Stueland's transition agreement provides accelerated vesting of RSUs that would otherwise have vested in March 2027, subject to a release of claims.
Source: SEC EDGAR, Form 8-K, Items 5.02, 7.01, 9.01, accession 0001104659-26-129358.
Written from the filing by Shamburg Markets. Figures are as reported by the company.